PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Completed · Phase 2

Conditions studied: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic neuroendocrine tumors.

Key facts

Study ID

NCT00017199

Run by

Ohio State University Comprehensive Cancer Center

Starts

2001-04-01

Expected to finish

2007-05-01

Last updated by the study team

2013-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.